5-氟尿嘧啶耐药在结直肠癌治疗中的研究进展  

Research Progress of 5-fluorouracil Resistance in the Treatment of Colorectal Cancer

作　　者：张思楠 张丽娜[2] Zhang Si’nan;Zhang Li’na(Jiamusi University,Jiamusi 154007;Daqing Oilfield General Hospital,Daqing 163411,China)

机构地区：[1]佳木斯大学,黑龙江佳木斯154007 [2]大庆油田总医院,黑龙江大庆163411

出　　处：《广东化工》2023年第2期90-91,120,共3页Guangdong Chemical Industry

摘　　要：结直肠癌(CRC)是全球最常见的癌症之一,发病率和死亡率都很高。5-氟尿嘧啶(5-FU)是CRC患者化疗的一线推荐药物,也是用于治疗CRC的基石药物。随着对其作用机制了解的增加,在过去的几十年中,已经开发了各种治疗方式以增加其抗癌活性。但CRC仍具有较高的发病率,化疗耐药仍是CRC治疗的主要障碍之一。结论:在本文中,我们系统地回顾和更新了5-FU耐药机理和其与氟尿嘧啶联合用药治疗结直肠癌的现有知识。因此本文就氟尿嘧啶耐药在结直肠癌治疗中的研究进展进行综述。Colorectal cancer(CRC)is one of the most common cancers worldwide,with high morbidity and mortality.5-fluorouracil(5-FU)is a recommended first-line chemotherapy agent for CRC patients and a cornerstone drug for the treatment of CRC.As the understanding of its mechanism of action has increased,various therapies have been developed over the past decades to increase its anticancer activity.However,CRC still has a high incidence,chemotherapy resistance is still one of the main obstacles to CRC treatment.Conclusions:In this study,we systematically reviewed and updated the current knowledge on the mechanism of 5-FU resistance and its combination with fluorouracil in the treatment of colorectal cancer.Therefore,this article reviews the research progress of fluorouracil resistance in the treatment of colorectal cancer.

关 键 词：5-氟尿嘧啶 化疗耐药 抗药性 肿瘤 胸苷酸合酶(TS) 胸苷磷酸化酶(TP) 二氢嘧啶脱氢酶(DPD) 

分 类 号：TQ[化学工程]